- Lilly's triple agonist heads to regulators after two more Phase 3 obesity winsRetatrutide, the obesity candidate that has shown the most powerful weight loss in late-stage trials, will be filed for approval early next year, its developer Eli Lilly said Thursday. The filing h…Endpoints · 6d ago↗ source
- Roche says it is thoughtful on token use for AI, shelves a drug from Carmot buyRoche has offered some insight into how it is using AI, from drug discovery to token use. AI has already contributed to “a significant increase in new molecules” in its pipeline, CEO Thomas Schinec…Endpoints · 6d ago↗ source
- Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts nearLong-acting obesity pill developer Verdiva Bio has a new chief medical officer, and he comes from a biotech that was looking at very similar technology — and got bought for $10 billion not long ago…